NCT03179501 is a Phase 1 clinical trial of NP001 in Alzheimer Disease, sponsored by Beau Nakamoto.

Who is sponsoring NCT03179501?

NCT03179501 is sponsored by Beau Nakamoto.

What drugs are being tested in NCT03179501?

Interventions in NCT03179501: NP001, Placebo.

What condition does NCT03179501 study?

NCT03179501 studies Alzheimer Disease.

Is NCT03179501 still recruiting?

NCT03179501 is currently terminated. Last updated 22 October 2018.

Last reviewed 2018-10-22 · How we verify

NCT03179501

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Terminated Phase 1 Last updated 22 October 2018

What this trial tests

Phase 1 trial testing NP001 in Alzheimer Disease in 4 participants. Terminated before completion.

Timeline

1 September 2017

Primary endpoint
31 July 2018

31 July 2018

Quick facts

Lead sponsor	Beau Nakamoto
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	4
Start date	1 September 2017
Primary completion	31 July 2018
Estimated completion	31 July 2018
Sites	1 location across United States

Drugs / interventions tested

NP001 — full drug profile →
Placebo

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Beau Nakamoto

Who can join

55 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 placebo-controlled biomarker study of NP001 in individuals with Alzheimer's Disease.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2018.
Cummings J, Lee G, Ritter A, Zhong K. · · 2018 · cited 402× · PMID 29955663 · DOI 10.1016/j.trci.2018.03.009
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease.
Hampel H, Caraci F, Cuello AC, Caruso G, et al · · 2020 · cited 264× · PMID 32296418 · DOI 10.3389/fimmu.2020.00456
Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease.
Dhapola R, Hota SS, Sarma P, Bhattacharyya A, et al · · 2021 · cited 254× · PMID 34813026 · DOI 10.1007/s10787-021-00889-6
The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?
Chatanaka MK, Prassas I, Masters CL, Diamandis EP. · · 2025 · cited 1× · PMID 40696840 · DOI 10.1002/alz.70484
Conventional and Emerging Drug Targeting Sites in Alzheimer's Disease and the Role of Translational Informatics in its Diagnosis and Management.
Khan KA, Esa M, Kamal Z, Ullah B, et al · · 2025 · cited 1× · PMID 40207764 · DOI 10.2174/011570159x361867250313073624

Verify or expand the search:

Other trials of NP001

Trials testing the same drug.

NCT02794857 — Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation · Phase 2 · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03179501 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beau Nakamoto
Last refreshed: 22 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03179501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing